Kate Johnson

4 days ago | medscape.com | Kate Johnson

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in the phase 3 ATOMIC trial. “These data established this combination as a new standard treatment for patients with stage III colon cancer and deficient mismatch repair,” said study author Frank A.

6 days ago | deutsch.medscape.com | Kate Johnson

Chicago – Die Kombination einer Chemotherapie mit sogenannten Tumor Treating Fields (TTFields) hat in einer Phase-3-Studie das Überleben von Patientinnen und Patienten mit lokal fortgeschrittenem, nicht resezierbarem Pankreaskarzinom (LA-PAC) signifikant verlängert. Damit liefert die PANOVA-3-Studie erstmals den Nachweis, dass eine Intervention als Ergänzung der Standard-Chemotherapie das Gesamtüberleben in dieser schlecht behandelbaren Patientengruppe verbessern könnte.

6 days ago | medscape.com | Kate Johnson

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was associated with significantly improved overall survival in a phase 3 trial for patients with unresectable, locally advanced, pancreatic adenocarcinoma (LA-PAC). The PANOVA-3 trial “establishes tumor treating fields with gemcitabine/nab-paclitaxel as a potential new standard treatment paradigm for unresectable, locally advanced pancreatic cancer,” reported Vincent J.

6 days ago | medscape.com | Kate Johnson

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer.

1 week ago | medscape.com | Kate Johnson

Autism spectrum disorder (ASD) is linked to a fourfold increased risk for early-onset Parkinson’s disease (PD), results from the largest, population-based cohort study of its kind to date showed. The findings indicated “that there can be shared biological drivers behind ASD and Parkinson’s disease,” study investigator, Weiyao Yin, MD, PhD, of the Karolinska Institutet in Stockholm, Sweden, said in .